Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density

G M Hall, L A Perry, T D Spector

Abstract
The sex hormones dehydroepiandrosterone sulphate (DHEAS), oestradiol, and sex hormone binding globulin (SHBG) were measured in 185 postmenopausal women (aged 45–65 years) with rheumatoid arthritis (RA) and related to assessments of bone mineral density at the spine and proximal femur. Compared with 518 postmenopausal control women (aged 45–65 years), DHEAS levels were below normal in the 120 patients with RA who had never taken corticosteroids and levels were further depressed in 39 patients currently using steroids. Twenty six patients who had completed steroid treatment also had lower DHEAS levels, suggesting a delayed recovery of adrenal androgen secretion. Oestradiol and SHBG levels were similar in all groups. There was no correlation between sex hormones and disease activity. Oestradiol correlated with bone mineral density at all sites. Although oestradiol correlated with DHEAS, there was no relation between DHEAS and bone mineral density. The cause of below normal levels of DHEAS in RA is unclear, whether a consequence of chronic illness, immune dysfunction, or a defect of adrenal androgen synthesis.

(Ann Rheum Dis 1993; 52: 211–214)

There has been considerable interest in the role of sex hormones in the aetiopathogenesis of rheumatoid arthritis (RA), based on the observed effects of gender, pregnancy, and exogenous oestrogens on the disease. Defective androgen synthesis in men and women has been proposed as a potential predisposing factor for RA, though others suggest low androgen levels to be a secondary phenomenon of chronic disease. Studies of dehydroepiandrosterone sulphate (DHEAS) levels in women with RA have yielded conflicting results; decreased, increased, and normal levels have been reported. Dehydroepiandrosterone sulphate is the most abundant androgen in normal postmenopausal women and despite being linked with atherosclerosis, diabetes, and hyperlipidaemia, its role remains to be established. Other studies have suggested that DHEAS may be important in maintaining skeletal mass in normal women and in women with RA. Most of these studies have used small numbers of patients and often inappropriate control groups. The aims of this study were to assess sex hormone status and the relation with bone density in a large group of postmenopausal women with RA and matched controls. Based on previous work, we decided to examine three sex steroids in detail: DHEAS, as the most abundant androgen; oestradiol, as the most active oestrogen; and sex hormone binding globulin (SHBG), a carrier protein that is a marker of free androgen and oestrogen.

Patients and methods
One hundred and eighty five postmenopausal women (aged 45–65 years) with definite RA were recruited from five rheumatology centres in northeast London. Patients were defined as postmenopausal if their last menstrual period had been more than one year ago or follicle stimulating hormone was greater than 15 IU/l. Exclusion criteria included present use of hormone replacement therapy (HRT) and concurrent illnesses that might affect bone mass.

All assessments of disease activity were made by the same observer and included the Ritchie articular index, Health Assessment Questionnaire (HAQ), early morning stiffness, 10 cm visual analogue pain scale, and the erythrocyte sedimentation rate (ESR). Details of previous and current steroid treatment were recorded according to medical records, treatment cards, and patient recollection. Cumulative dose was calculated from the mean daily dose multiplied by the number of months of treatment.

Blood samples were taken at the same time of day in each patient (1400–1600 hours). Serum concentrations of oestradiol, SHBG, and DHEAS were measured using radioimmunoassay with a coefficient of variation of less than 10%. Bone density was measured at the lumbar spine L1–L4 and proximal femur using dual energy x ray absorptiometry (Hologic QDR 1000/W). In 53 consecutive patients whole body bone density was also measured.

The control group consisted of 518 postmenopausal women (aged 45–65 years) who agreed to participate in a population
screening programme for bone and joint disease and had never received HRT.

In view of the known effects of corticosteroids on bone and sex hormones, patients were analysed by three groups: those who had never taken steroids (never users, 120 women), those who had taken steroids in the past (ex users, 26 women), and those currently maintained on steroids (current users, 39 women). Serum hormone concentrations showed a non-normal distribution and statistical analyses were made using Student’s t test following logarithmic transformation of the data. Levels of oestradiol and DHEAS below the sensitivity of the assays were given a value equal to the lowest recordable concentration (20 pmol/l and 0.2 μmol/l respectively). Variables were compared using Pearson’s correlation test.

Results

Table 1 lists the disease characteristics of the three RA groups and the controls. The current steroid users, never users, and controls were similar in age, since the menopause, and weight. There were no significant differences in parameters of disease activity. Compared with never users, ex users were significantly lighter (p<0.01), had a later menopause (p=0.03), and had a higher HAQ score (p<0.001).

The serum concentration of DHEAS was significantly lower in all RA groups compared with controls (p<0.001) (table 2). Lowest values were seen in the current users (p<0.001 v never users), and even ex users had significantly decreased levels compared with never users (p=0.02). Log SHBG and oestradiol values in the never users and steroid users were similar to controls. The DHEAS level did not correlate significantly with any of the parameters of disease activity (table 3), but did correlate with oestradiol (r=0.38; p<0.001) and was inversely related to age (r=-0.31; p<0.01).

Bone mineral density values have been discussed in detail elsewhere and are as follows: lumbar spine controls 0.93 g/cm², never users 0.92 g/cm², ex users 0.93 g/cm², current users 0.85 g/cm²; proximal femur controls 0.87 g/cm², never users 0.81 g/cm², ex users 0.79 g/cm², current users 0.74 g/cm². There was no relation between DHEAS and bone mineral density at either measured site. Concentrations of oestradiol were inversely related to years since the menopause (r=-0.45; p<0.001) and age (r=-0.55; p<0.001) as expected, but not weight. There were consistent correlations between oestradiol and bone mineral density at all sites. The SHBG level did not correlate with other hormones or with bone mineral density. The SHBG levels decreased with increased weight (r=0.41; p<0.001), and this relation was also seen in controls.

Discussion

The possible role of androgens as disease mediators in RA has attracted particular interest as subnormal levels have been consistently reported in men with RA, though levels in women are less conclusive. Dehydroepiandrosterone sulphate is the most abundant circulating androgen in post-menopausal women and exists as a large circulating pool formed principally by the peripheral sulphation of dehydroepiandrosterone (DHEA), with which it can be interconverted. Dehydroepiandrosterone is secreted by the adrenal cortex under the control of adrenocorticotropic hormone and, to a much lesser extent, by the postmenopausal ovary. Labelling studies suggest DHEAS may

---

Table 1  Characteristics of patients with rheumatoid arthritis (RA) and controls

<table>
<thead>
<tr>
<th>Mean (SD) variable</th>
<th>Patients with RA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Never steroids</td>
</tr>
<tr>
<td></td>
<td>(n=120)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>56.0(5.0)</td>
</tr>
<tr>
<td>Years since menopause</td>
<td>8.3(0.1)*</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>65.9(11.8)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>13.2(8.3)</td>
</tr>
<tr>
<td>Health Assessment Questionnaire score</td>
<td>3.0(0.8)</td>
</tr>
<tr>
<td>Ritchie articular index</td>
<td>10.4(5.1)</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (mm/hour)</td>
<td>32.7(22.7)</td>
</tr>
<tr>
<td>Early morning stiffness (min)</td>
<td>40.2(45.0)</td>
</tr>
</tbody>
</table>

*p<0.01, †p<0.001, ‡p<0.0001

Table 2  Hormone concentrations in patients with rheumatoid arthritis (RA) and control groups. Note all statistical comparisons based on log transformed data.

<table>
<thead>
<tr>
<th>Mean (SD) variable</th>
<th>Patients with RA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Never steroids</td>
</tr>
<tr>
<td></td>
<td>(n=120)</td>
</tr>
<tr>
<td>DHEAS (μmol/l)*</td>
<td>3.063(3.57)†</td>
</tr>
<tr>
<td>SHBG (nmol/l)*</td>
<td>57.6(26.4)</td>
</tr>
<tr>
<td>Oestradiol (pmol/l)</td>
<td>81.4(19.5)</td>
</tr>
</tbody>
</table>

*DHEAS=dehydroepiandrosterone sulphate; SHBG=sex hormone binding globulin.

Table 3  Correlations (r values) between sex hormones, disease characteristics, and bone mineral density in patients with rheumatoid arthritis who have never used steroids

<table>
<thead>
<tr>
<th></th>
<th>Oestradiol</th>
<th>SHBG*</th>
<th>DHEAS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>-0.55†</td>
<td>-0.11</td>
<td>-0.31‡</td>
</tr>
<tr>
<td>Years since menopause</td>
<td>-0.35†</td>
<td>-0.13</td>
<td>-0.24‡</td>
</tr>
<tr>
<td>Weight</td>
<td>-0.1</td>
<td>-0.41‡</td>
<td>-0.09</td>
</tr>
<tr>
<td>Health Assessment</td>
<td>-0.17</td>
<td>-0.10</td>
<td>-0.10</td>
</tr>
<tr>
<td>Ritchie articular index</td>
<td>-0.12</td>
<td>-0.14</td>
<td>-0.13</td>
</tr>
<tr>
<td>Early morning</td>
<td>-0.16</td>
<td>-0.12</td>
<td>-0.13</td>
</tr>
<tr>
<td>Visual analogue pain</td>
<td>-0.11</td>
<td>-0.03</td>
<td>-0.13</td>
</tr>
<tr>
<td>Erythrocyte sedimentation</td>
<td>-0.17</td>
<td>-0.1</td>
<td>-0.13</td>
</tr>
<tr>
<td>Bone mineral density</td>
<td>-0.28</td>
<td>-0.09</td>
<td>0.06</td>
</tr>
<tr>
<td>Bone mineral density</td>
<td>-0.29</td>
<td>-0.09</td>
<td>0.06</td>
</tr>
<tr>
<td>Bone mineral density</td>
<td>0.42‡</td>
<td>-0.12</td>
<td>-0.04</td>
</tr>
</tbody>
</table>

*DHEAS=dehydroepiandrosterone sulphate; SHBG=sex hormone binding globulin.
P<0.01
Decreased levels of DHEAS in postmenopausal women with RA

be interchangeable with other androgens such as androstenedione,16 19 itself an important source of postmenopausal oestrogen.20 Low DHEA and DHEAS levels have been reported in patients with postmenopausal osteoporosis1 and correlations found with bone density in normal20 21 and rheumatoid subjects.22 Androgens may have important effects on immunological pathways. Daynes et al reported that DHEA enhances the synthesis of interleukin 2 by helper T cells21 and Risdon et al found that DHEA inhibited murine natural killer cell differentiation.22 Androgen status in women with RA has previously been examined in a number of small studies. Masi et al found subnormal basal excretion of 17 ketosteroids, especially DHEAS, a blunted response to ACTH, and a failure to increase excretion following metyrapone, leading them to conclude that there may be a primary defect of androgen synthesis in RA.1 Urine excretion studies may also reflect abnormalities of hormone degradation, however, and subnormal 17 ketosteroid urine excretion rates have also been found in patients with gout and diabetes.3 Studies of serum androgens in women with RA have yielded conflicting results. Feher et al reported lower levels of testosterone and DHEAS in 77 women with RA (47 postmenopausal) and also found a negative correlation between DHEAS and disease activity.6 Sambrook et al found subnormal DHEAS levels in 27 postmenopausal women who were not taking steroids but levels did not correlate with disease duration or functional class.5 Conversely, a small Italian study of 14 postmenopausal patients with RA found increased levels of DHEAS, testosterone, and androstenedione8 compared with 12 controls and another study found normal androgen levels in 19 postmenopausal patients with RA.7 Interestingly, the latter two studies used patients with osteoarthritis as controls and DHEAS levels were considerably lower in these two control groups than in our own normal population. Furthermore, some patients with osteoarthritis may themselves be hormonally different.23 Our data are derived from a substantially larger group of patients with RA and controls than previously examined, and confirm that DHEAS levels are subnormal. Whether this observation is a primary or secondary event in RA is unclear. It has been previously shown that chronic diseases may interfere with androgen metabolism:2 Semple et al looked at 32 men with acute and long term illnesses and found that DHEAS levels only became decreased in patients who had been ill for at least two weeks.2 Patients with chronic illness are usually receiving drugs and clearly drug treatment may be a possible confounder in studies of peripheral metabolic pathways. Although it seems likely that levels of DHEAS should be influenced by the effect of disease on peripheral metabolism, we were unable to find a clear relation between DHEAS and disease activity even with large study numbers. A defect of androgen synthesis in RA, with consequent effects on immune mechanisms, remains a possible explanation for our results. This adrenal defect has been postulated as primary,1,12 though some work has suggested a primary defect of the hypothalamus in RA.24 In contrast with Sambrook et al,2 we were unable to find a correlation between bone density and DHEAS. Sambrook et al reported that DHEAS was a significant predictor of bone density at the femoral neck but not the lumbar spine. A number of population studies have also found weak relations between osteoporosis and DHEAS. Spector et al reported a correlation between DHEAS and spinal but not femoral bone mass10 and Nordin et al found lower DHEAS levels in women with postmenopausal fractures but no significant correlation between bone mass and DHEAS.9 Another study of postmenopausal women correlated DHEAS with forearm bone mass and vitamin D levels, but the two relations became insignificant after adjustment for age.11 Serum oestradiol levels in the RA and control groups were similar, confirming the findings of previous smaller studies.3 8 25 Levels were often below the detectable range of the assay and results should therefore be interpreted cautiously—nevertheless, oestradiol correlated with bone mineral density at all sites, confirming its importance in the maintenance of the postmenopausal skeleton. There was a significant correlation between oestradiol and DHEAS. Taelman et al showed a relation between DHEA and oestrone14 and others have shown interconversion of DHEAS with other androgens,16 31 suggesting that the DHEAS pool may help provide androgen substrate for conversion to oestrogens. This may be an explanation for the previously described relations between DHEAS and bone mass.

Current steroid users showed further decreases of DHEAS levels, likely to be a direct result of reduced ACTH dependent secretion of DHEA, as previously shown.17 26 27 Oestradiol levels were not suppressed by prednisolone, probably reflecting continued secretion of ovarian androgens.17 28 The lower values of DHEAS in ex steroid users is surprising, but suggests a delayed recovery of adrenal androgen secretion following cessation of steroid treatment as reported in a patient by Cutler et al.27

In summary, we have found low levels of DHEAS in a large group of postmenopausal women with RA but normal levels of oestradiol and SHBG. As DHEAS values did not correlate with disease activity, we cannot explain these findings on the basis of the effects of chronic illness on androgen metabolism. Dynamic studies would help in our further understanding of the metabolism of androgens in RA, their possible interactive role on pathological mechanisms and their potential therapeutic role in RA.

We are grateful to all the staff involved with DEXA scanning and to the doctors and general practitioners whose patients were recruited.


Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density.

G M Hall, L A Perry and T D Spector

Ann Rheum Dis 1993 52: 211-214
doi: 10.1136/ard.52.3.211

Updated information and services can be found at:
http://ard.bmj.com/content/52/3/211

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/